Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …

We appreciate the interest on the 2020 European Society of Cardiology (ESC) guidelines for
the management of acute coronary syndromes (ACS) in patients presenting without …

Background In patients with non–ST-segment elevation acute coronary syndrome
(NSTEACS), coronary pathology may range from structurally normal vessels to severe …

Background Current guidelines recommend intensified platelet inhibition by prasugrel or
ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) …

Background: Immature or reticulated platelets are associated with impaired efficacy of
antiplatelet drugs and adverse events in cardiovascular patients. Their role as a predictive …

Importance It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients
with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) …

Aim To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might
represent a suitable way to reach a proper antiaggregation in acute coronary syndrome …

Abstract Background Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly
utilized across the clinical spectrum of patients undergoing percutaneous coronary …

Objectives The aim of this study was to assess the safety and efficacy of ticagrelor versus
prasugrel for patients with acute coronary syndrome (ACS) according to their estimated …